Cargando…

Biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer

BACKGROUND: Triple-negative breast cancer (TNBC) is a kind of aggressive breast cancer with a high rate of metastasis, poor overall survival time, and a low response to targeted therapies. To improve the therapeutic efficacy and overcome the drug resistance of TNBC treatments, here we developed the...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Hanyi, Gai, Yongkang, Wang, Sheng, Liu, Qingyao, Zhang, Xiao, Ye, Min, Tan, Jianling, Long, Yu, Wang, Kuanyin, Zhang, Yongxue, Lan, Xiaoli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981819/
https://www.ncbi.nlm.nih.gov/pubmed/33743740
http://dx.doi.org/10.1186/s12951-021-00827-2
_version_ 1783667592402042880
author Fang, Hanyi
Gai, Yongkang
Wang, Sheng
Liu, Qingyao
Zhang, Xiao
Ye, Min
Tan, Jianling
Long, Yu
Wang, Kuanyin
Zhang, Yongxue
Lan, Xiaoli
author_facet Fang, Hanyi
Gai, Yongkang
Wang, Sheng
Liu, Qingyao
Zhang, Xiao
Ye, Min
Tan, Jianling
Long, Yu
Wang, Kuanyin
Zhang, Yongxue
Lan, Xiaoli
author_sort Fang, Hanyi
collection PubMed
description BACKGROUND: Triple-negative breast cancer (TNBC) is a kind of aggressive breast cancer with a high rate of metastasis, poor overall survival time, and a low response to targeted therapies. To improve the therapeutic efficacy and overcome the drug resistance of TNBC treatments, here we developed the cancer cell membrane-coated oxygen delivery nanoprobe, CCm–HSA–ICG–PFTBA, which can improve the hypoxia at tumor sites and enhance the therapeutic efficacy of the photodynamic therapy (PDT), resulting in relieving the tumor growth in TNBC xenografts. RESULTS: The size of the CCm–HSA–ICG–PFTBA was 131.3 ± 1.08 nm. The in vitro (1)O(2) and ROS concentrations of the CCm–HSA–ICG–PFTBA group were both significantly higher than those of the other groups (P < 0.001). In vivo fluorescence imaging revealed that the best time window was at 24 h post-injection of the CCm–HSA–ICG–PFTBA. Both in vivo (18)F-FMISO PET imaging and ex vivo immunofluorescence staining results exhibited that the tumor hypoxia was significantly improved at 24 h post-injection of the CCm–HSA–ICG–PFTBA. For in vivo PDT treatment, the tumor volume and weight of the CCm–HSA–ICG–PFTBA with NIR group were both the smallest among all the groups and significantly decreased compared to the untreated group (P < 0.01). No obvious biotoxicity was observed by the injection of CCm–HSA–ICG–PFTBA till 14 days. CONCLUSIONS: By using the high oxygen solubility of perfluorocarbon (PFC) and the homologous targeting ability of cancer cell membranes, CCm–HSA–ICG–PFTBA can target tumor tissues, mitigate the hypoxia of the tumor microenvironment, and enhance the PDT efficacy in TNBC xenografts. Furthermore, the HSA, ICG, and PFC are all FDA-approved materials, which render the nanoparticles highly biocompatible and enhance the potential for clinical translation in the treatment of TNBC patients. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-00827-2.
format Online
Article
Text
id pubmed-7981819
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-79818192021-03-22 Biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer Fang, Hanyi Gai, Yongkang Wang, Sheng Liu, Qingyao Zhang, Xiao Ye, Min Tan, Jianling Long, Yu Wang, Kuanyin Zhang, Yongxue Lan, Xiaoli J Nanobiotechnology Research BACKGROUND: Triple-negative breast cancer (TNBC) is a kind of aggressive breast cancer with a high rate of metastasis, poor overall survival time, and a low response to targeted therapies. To improve the therapeutic efficacy and overcome the drug resistance of TNBC treatments, here we developed the cancer cell membrane-coated oxygen delivery nanoprobe, CCm–HSA–ICG–PFTBA, which can improve the hypoxia at tumor sites and enhance the therapeutic efficacy of the photodynamic therapy (PDT), resulting in relieving the tumor growth in TNBC xenografts. RESULTS: The size of the CCm–HSA–ICG–PFTBA was 131.3 ± 1.08 nm. The in vitro (1)O(2) and ROS concentrations of the CCm–HSA–ICG–PFTBA group were both significantly higher than those of the other groups (P < 0.001). In vivo fluorescence imaging revealed that the best time window was at 24 h post-injection of the CCm–HSA–ICG–PFTBA. Both in vivo (18)F-FMISO PET imaging and ex vivo immunofluorescence staining results exhibited that the tumor hypoxia was significantly improved at 24 h post-injection of the CCm–HSA–ICG–PFTBA. For in vivo PDT treatment, the tumor volume and weight of the CCm–HSA–ICG–PFTBA with NIR group were both the smallest among all the groups and significantly decreased compared to the untreated group (P < 0.01). No obvious biotoxicity was observed by the injection of CCm–HSA–ICG–PFTBA till 14 days. CONCLUSIONS: By using the high oxygen solubility of perfluorocarbon (PFC) and the homologous targeting ability of cancer cell membranes, CCm–HSA–ICG–PFTBA can target tumor tissues, mitigate the hypoxia of the tumor microenvironment, and enhance the PDT efficacy in TNBC xenografts. Furthermore, the HSA, ICG, and PFC are all FDA-approved materials, which render the nanoparticles highly biocompatible and enhance the potential for clinical translation in the treatment of TNBC patients. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12951-021-00827-2. BioMed Central 2021-03-20 /pmc/articles/PMC7981819/ /pubmed/33743740 http://dx.doi.org/10.1186/s12951-021-00827-2 Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Fang, Hanyi
Gai, Yongkang
Wang, Sheng
Liu, Qingyao
Zhang, Xiao
Ye, Min
Tan, Jianling
Long, Yu
Wang, Kuanyin
Zhang, Yongxue
Lan, Xiaoli
Biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer
title Biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer
title_full Biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer
title_fullStr Biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer
title_full_unstemmed Biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer
title_short Biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer
title_sort biomimetic oxygen delivery nanoparticles for enhancing photodynamic therapy in triple-negative breast cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7981819/
https://www.ncbi.nlm.nih.gov/pubmed/33743740
http://dx.doi.org/10.1186/s12951-021-00827-2
work_keys_str_mv AT fanghanyi biomimeticoxygendeliverynanoparticlesforenhancingphotodynamictherapyintriplenegativebreastcancer
AT gaiyongkang biomimeticoxygendeliverynanoparticlesforenhancingphotodynamictherapyintriplenegativebreastcancer
AT wangsheng biomimeticoxygendeliverynanoparticlesforenhancingphotodynamictherapyintriplenegativebreastcancer
AT liuqingyao biomimeticoxygendeliverynanoparticlesforenhancingphotodynamictherapyintriplenegativebreastcancer
AT zhangxiao biomimeticoxygendeliverynanoparticlesforenhancingphotodynamictherapyintriplenegativebreastcancer
AT yemin biomimeticoxygendeliverynanoparticlesforenhancingphotodynamictherapyintriplenegativebreastcancer
AT tanjianling biomimeticoxygendeliverynanoparticlesforenhancingphotodynamictherapyintriplenegativebreastcancer
AT longyu biomimeticoxygendeliverynanoparticlesforenhancingphotodynamictherapyintriplenegativebreastcancer
AT wangkuanyin biomimeticoxygendeliverynanoparticlesforenhancingphotodynamictherapyintriplenegativebreastcancer
AT zhangyongxue biomimeticoxygendeliverynanoparticlesforenhancingphotodynamictherapyintriplenegativebreastcancer
AT lanxiaoli biomimeticoxygendeliverynanoparticlesforenhancingphotodynamictherapyintriplenegativebreastcancer